COAPTIUM Connect
Phase 1- Indications
- Peripheral nerve repair
Company intelligence / Profile preview
TISSIUM has developed a proprietary family of fully synthetic, biomorphic programmable polymers designed for atraumatic tissue reconstruction across multiple surgical specialties. The technology enables on-demand polymerization with high biocompatibility and bioresorbability. The company holds three CE Marks and has treated first patients with its hernia system. Its lead programs target peripheral nerve repair, cardiovascular sealing, gastrointestinal surgery, and hernia treatment. Clinical results show successful tissue integration and healing with minimal trauma compared to traditional sutures or tacks.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TISSIUM.